EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.47 | decay accelerating factor |
DAF, mediates decay acceleration of the C3bBb complex |
 |
| 3.4.21.47 | decay-accelerating factor |
DAF, CD55, major site of interaction with the larger cleavage subunit complement component factor B (Bb), interaction pathway dissected, second short consensus repeat (SCR) domain of DAF (SCR2) interacts only with fragment Bb, whereas SCR4 interacts with complement component C3b, SCR3 does not directly interact with either subunit |
|
| 3.4.21.47 | diisopropyl phosphate |
- |
  |
| 3.4.21.47 | eculizumab |
- |
|
| 3.4.21.47 | eculizumab |
the inhibitor specifically interfers with C5 conversion but not C3 conversion |
|
| 3.4.21.47 | EDTA |
- |
|
| 3.4.21.47 | Efb-C |
C-terminal region of extracellular fibrinogen binding protein. The inhibitor specifically blocks C5 conversion, while leaving C3 conversion unaffected |
|
| 3.4.21.47 | extracellular complement binding protein |
the inhibitor specifically blocks C5 conversion, while leaving C3 conversion unaffected |
|
| 3.4.21.47 | factor H |
mediates decay acceleration of the C3bBb complex |
|
| 3.4.21.47 | factor H |
a well known inhibitor of the alternative complement pathway |
|
